DrugPatentWatch Database Preview
LYSTEDA Drug Profile
or, see our see our flat-rate plans
When do Lysteda patents expire, and when can generic versions of Lysteda launch?
This drug has eight patent family members in two countries.
The generic ingredient in LYSTEDA is tranexamic acid. There are seven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the tranexamic acid profile page.
Summary for LYSTEDA
| International Patents: | 8 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 156 |
| Clinical Trials: | 11 |
| Patent Applications: | 3,168 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LYSTEDA |
| DailyMed Link: | LYSTEDA at DailyMed |
Pharmacology for LYSTEDA
| Drug Class | Antifibrinolytic Agent |
| Physiological Effect | Decreased Fibrinolysis |
Medical Subject Heading (MeSH) Categories for LYSTEDA
Synonyms for LYSTEDA
| (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid |
| (trans)-4-(aminomethyl)cyclohexanecarboxylic acid |
| 1197-17-7 |
| 1197-18-8 |
| 1510-00-5 |
| 197T188 |
| 1ceb |
| 204139-EP2277867A2 |
| 204139-EP2280003A2 |
| 21573-60-4 |
| 3-14-00-00868 (Beilstein Handbook Reference) |
| 37YD696II6 |
| 4-(Aminomethyl)-Cyclohexanecarboxylic Acid |
| 4-(aminomethyl)cyclohexane-1-carboxylic acid |
| 4-(Aminomethyl)cyclohexanecarboxylic acid |
| 4-(Aminomethyl)cyclohexanecarboxylic Acid (cis- and trans- mixture) |
| 4-Aminomethyl-cyclohexanecarboxylic acid |
| 4-aminomethylcyclohexanecarboxylic acid |
| 4-trans-(Aminomethyl)cyclohexanecarboxylic acid # |
| 4alpha-Aminomethyl-1alpha-cyclohexanecarboxylic acid |
| 6T84R30KC1 |
| 701-54-2 |
| 701-54-2 (cis+trans) |
| 701-54-2 tranexamic acid |
| A0236 |
| AB00052260 |
| AB00052260_05 |
| AB00052260_06 |
| AB00052260-04 |
| AB0013391 |
| AB1003647 |
| AC-4687 |
| AC1L1KJH |
| AC1Q50F3 |
| AC1Q546D |
| AC1Q5U04 |
| Acide tranexamique |
| Acide tranexamique [INN-French] |
| Acido tranexamico |
| Acido tranexamico [INN-Spanish] |
| Acidum tranexamicum |
| Acidum tranexamicum [INN-Latin] |
| ACMC-209a3u |
| ACMC-20h19o |
| AJ-26859 |
| AK134863 |
| AK516712 |
| AKOS005171632 |
| AKOS015854573 |
| AKOS024257901 |
| ALBB-006013 |
| AM84352 |
| AMCA |
| AMCA|||AMCHA|||HAKU|||TAMCHA |
| AMCHA |
| Amchafibrin |
| AMH |
| Amikapron |
| Amstat |
| AN-47328 |
| AN-646 |
| Anvitoff |
| ANW-17368 |
| BAY 3517 |
| BB 0260034 |
| BBL004469 |
| BC215624 |
| BDBM50428067 |
| BP-12345 |
| BPBio1_000069 |
| BRD-K15014948-001-01-2 |
| BRN 2207452 |
| BS-3867 |
| BSPBio_000061 |
| BSPBio_002837 |
| C-5054 |
| C12535 |
| Carxamin |
| CAS-1197-18-8 |
| CCG-39692 |
| CHEBI:48669 |
| CHEBI:94518 |
| CHEMBL292500 |
| CHEMBL877 |
| cis-4-(Aminomethyl)-1-cyclohexanecarboxylic Acid |
| cis-4-(Aminomethyl)cyclohexanecarboxylic acid |
| cis-4-aminomethyl-1-cyclohexanecarboxylic acid |
| cis-4-Aminomethylcyclohexane-1-carboxylic acid |
| cis-AMCHA |
| cis-Tranexamic Acid |
| CL 65336 |
| CL-65336 |
| CS-1965 |
| CTK0H8184 |
| CTK3I9745 |
| Cyclo-F |
| Cyclocapron |
| Cyclohexanecarboxylic acid, 4-(aminomethyl)- |
| Cyclohexanecarboxylic acid, 4-(aminomethyl)-, cis- |
| Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- |
| Cyclohexanecarboxylicacid, 4-(aminomethyl)-, cis- |
| Cyklokapron |
| Cyklokapron (TN) |
| D01136 |
| D05HXX |
| DB-074265 |
| DB00302 |
| DivK1c_000655 |
| DSSTox_CID_25350 |
| DSSTox_GSID_45350 |
| DSSTox_RID_80817 |
| DTXSID3045350 |
| DV 79 |
| DV-79 |
| DV79 |
| EINECS 214-818-2 |
| Emorhalt |
| EN300-91506 |
| Exacyl |
| F8886-7867 |
| Femstrual |
| FMOC-(R)-2-aminobutyric acid |
| Frenolyse |
| FT-0654339 |
| FT-0675360 |
| FT-0700806 |
| GTPL6573 |
| GYDJEQRTZSCIOI-KNVOCYPGSA-N |
| GYDJEQRTZSCIOI-LJGSYFOKSA-N |
| GYDJEQRTZSCIOI-UHFFFAOYSA-N |
| H967 |
| HAKU |
| Hexapromin |
| Hexatron |
| HMS1568D03 |
| HMS1921F08 |
| HMS2092P03 |
| HMS2095D03 |
| HMS502A17 |
| HTS001347 |
| HY-B0149 |
| I04-0993 |
| I14-15270 |
| IDI1_000655 |
| KABI 2161 |
| KB-271963 |
| KBio1_000655 |
| KBio2_001871 |
| KBio2_004439 |
| KBio2_007007 |
| KBio3_002337 |
| KBioGR_000511 |
| KBioSS_001871 |
| KS-00000IPI |
| KS-00000NS2 |
| KSC489O4L |
| LS-56611 |
| LS-56612 |
| LT00159441 |
| Mastop |
| MCULE-6087008336 |
| MFCD00001466 |
| MFCD00064951 |
| MolPort-001-792-390 |
| MolPort-002-512-008 |
| NCGC00016569-01 |
| NCGC00016569-02 |
| NCGC00016569-03 |
| NCGC00016569-04 |
| NCGC00016569-05 |
| NCGC00016569-06 |
| NCGC00016569-08 |
| NCGC00016569-09 |
| NCGC00094944-01 |
| NCGC00094944-02 |
| NINDS_000655 |
| NSC 291305 |
| NSC-291305 |
| NSC-758176 |
| NSC291305 |
| NSC758176 |
| Oprea1_786414 |
| OR041375 |
| OR176508 |
| OR208045 |
| OR208047 |
| p-(Aminomethyl)cyclohexanecarboxylic acid |
| Pharmakon1600-01502026 |
| Prestwick_476 |
| Prestwick0_000171 |
| Prestwick1_000171 |
| Prestwick2_000171 |
| Prestwick3_000171 |
| PubChem19810 |
| Q-201848 |
| Q-9390 |
| rel-(1R,4R)-4-(aminomethyl)cyclohexane-1-carboxylic acid |
| rel-(1r,4r)-4-(Aminomethyl)cyclohexanecarboxylic acid |
| Retavase |
| Rikavarin |
| Rikavarin (TN) |
| Rikavarin-S |
| RP 18,429 |
| RP22118 |
| RTX-010404 |
| s1875 |
| SBB006715 |
| SBI-0051705.P002 |
| SC-19036 |
| SC-90830 |
| SCHEMBL16974 |
| SCHEMBL186034 |
| SCHEMBL349408 |
| SCHEMBL6885575 |
| SCHEMBL9885628 |
| SPBio_000689 |
| SPBio_001982 |
| Spectrum_001391 |
| SPECTRUM1502026 |
| Spectrum2_000655 |
| Spectrum3_001189 |
| Spectrum4_000046 |
| Spectrum5_001258 |
| Spiramin |
| SR-05000001794 |
| SR-05000001794-3 |
| ST50307111 |
| STK503668 |
| STOCK1N-16183 |
| t-AMCHA |
| Tamcha |
| Tox21_110500 |
| TR-023271 |
| TRA0027406 |
| Tranesamic acid |
| Tranex |
| tranexamate |
| tranexamic acid |
| Tranexamic acid (JP15/USAN/INN) |
| Tranexamic acid (JP17/USAN/INN) |
| Tranexamic acid (Transamin) |
| Tranexamic acid [USAN:INN:BAN:JAN] |
| Tranexamic acid [USAN:USP:INN:BAN:JAN] |
| Tranexamic acid cis-form |
| Tranexamic acid, European Pharmacopoeia (EP) Reference Standard |
| Tranexamic acid, Pharmaceutical Secondary Standard; Certified Reference Material |
| Tranexamic acid, United States Pharmacopeia (USP) Reference Standard |
| Tranexamicacid |
| Tranexamsaeure |
| Tranexan |
| tranexmic acid |
| Tranhexamic acid |
| tranol |
| trans 4-aminomethylcyclohexanecarboxylic acid |
| trans 4aminomethylcyclohexanecarboxylic acid |
| Trans AMCHA |
| trans-?4-?(Aminomethyl)?cyclohexanecarboxylic acid |
| trans-1-(Aminomethyl)cyclohexane-4-carboxylic acid |
| trans-1-Aminomethylcyclohexane-4-carboxylic acid |
| trans-4 -(aminomethyl)cyclohexanecarboxylic acid |
| trans-4- (aminomethyl) cyclohexanecarboxylic acid |
| trans-4-(aminomethyl)- cyclohexane carboxylic acid |
| trans-4-(Aminomethyl)-1-cyclohexanecarboxylic acid |
| Trans-4-(aminomethyl)-cyclohexane carboxylic acid |
| trans-4-(aminomethyl)-cyclohexanecarboxylic acid |
| trans-4-(Aminomethyl)cyclohexane carboxylic acid |
| trans-4-(Aminomethyl)cyclohexane-1-carboxylic acid |
| trans-4-(Aminomethyl)cyclohexane-carboxylic acid |
| trans-4-(Aminomethyl)cyclohexanecarboxylic acid |
| trans-4-(Aminomethyl)cyclohexanecarboxylic acid (Tranexamic acid) |
| trans-4-(Aminomethyl)cyclohexanecarboxylic acid ester |
| trans-4-(Aminomethyl)cyclohexanecarboxylic acid, 97% |
| trans-4-(aminomethyl)cyclohexylcarboxylic acid |
| Trans-4-Aminomethyl cyclohexane carboxylic acid |
| trans-4-aminomethyl cyclohexanecarboxylic acid |
| trans-4-aminomethyl-1-cyclohexane carboxylic acid |
| trans-4-aminomethyl-1-cyclohexanecarboxylic acid |
| trans-4-aminomethyl-cyclohexanecarboxylic acid |
| trans-4-aminomethylcyclohexane carboxylic acid |
| trans-4-Aminomethylcyclohexane-1-carboxylic acid |
| trans-4-aminomethylcyclohexanecarboxylic acid |
| Trans-4-aminomethylcyclohexylcarboxylic acid |
| trans-4(aminomethyl)cyclohexanecarboxylic acid |
| trans-Amcha |
| Trans-p-(Aminomethyl)cyclohexanecarboxylic |
| trans-p-(Aminomethyl)cyclohexanecarboxylic acid |
| trans-p-Aminomethylcyclohexanecarboxylic acid |
| trans-Tranexamic acid |
| trans4-aminomethylcyclohexane-1-carboxylic acid |
| Transamin |
| Transamin (TN) |
| Transamlon |
| Trasamlon |
| TS-02090 |
| Ugurol |
| UNII-37YD696II6 |
| UNII-6T84R30KC1 |
| WLN: L6TJ AVQ D1Z -T |
| WT319 |
| Z1741970429 |
| zataranax |
| ZINC100007011 |
| ZINC100071256 |
| ZINC1542907 |
US Patents and Regulatory Information for LYSTEDA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Ferring Pharms Inc | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Ferring Pharms Inc | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Ferring Pharms Inc | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Paragraph IV (Patent) Challenges for LYSTEDA
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 650 mg | ➤ Subscribe | 2011-05-24 |
or, see our see our flat-rate plans
International Patents for LYSTEDA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006023001 | ➤ Sign Up |
| Japan | 5205053 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006023000 | ➤ Sign Up |
| Japan | 2008508276 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
